DNB Asset Management AS Acquires 8,770 Shares of Glaukos Corporation $GKOS

DNB Asset Management AS lifted its stake in Glaukos Corporation (NYSE:GKOS) by 11.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,320 shares of the medical instruments supplier’s stock after purchasing an additional 8,770 shares during the quarter. DNB Asset Management AS’s holdings in Glaukos were worth $9,295,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. UMB Bank n.a. raised its stake in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares during the last quarter. First Horizon Corp raised its stake in Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 223 shares during the last quarter. REAP Financial Group LLC purchased a new position in Glaukos during the third quarter valued at $40,000. Farther Finance Advisors LLC raised its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 215 shares during the last quarter. Finally, Salomon & Ludwin LLC raised its stake in Glaukos by 111.2% during the fourth quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GKOS shares. Stifel Nicolaus set a $170.00 price target on shares of Glaukos in a research note on Thursday, April 30th. BTIG Research upped their price target on shares of Glaukos from $131.00 to $141.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Needham & Company LLC upped their price target on shares of Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company upped their price target on shares of Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. upped their price target on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $144.42.

Glaukos Stock Performance

GKOS stock opened at $143.53 on Monday. The stock has a market capitalization of $8.43 billion, a PE ratio of -43.76 and a beta of 0.94. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $146.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The stock’s 50 day simple moving average is $117.10 and its 200 day simple moving average is $111.64.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. The business had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm’s quarterly revenue was up 41.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) EPS. As a group, research analysts forecast that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $135.00, for a total transaction of $675,000.00. Following the transaction, the director owned 35,528 shares in the company, valued at approximately $4,796,280. This represents a 12.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the transaction, the director owned 18,806 shares in the company, valued at $2,207,448.28. This represents a 44.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 55,930 shares of company stock worth $7,378,263. 5.90% of the stock is owned by company insiders.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.